These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19329185)

  • 1. Transcriptional activation of Skp2 by BCR-ABL in K562 chronic myeloid leukemia cells.
    Chen JY; Wang MC; Hung WC
    Leuk Res; 2009 Nov; 33(11):1520-4. PubMed ID: 19329185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcr-Abl-induced tyrosine phosphorylation of Emi1 to stabilize Skp2 protein via inhibition of ubiquitination in chronic myeloid leukemia cells.
    Chen JY; Wang MC; Hung WC
    J Cell Physiol; 2011 Feb; 226(2):407-13. PubMed ID: 20717963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
    Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I
    Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study on mismatch repair genes of chronic myeloid leukemia].
    Luo J; Peng ZG; Chen Y; Lai YR; Lu YY; Song SJ
    Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):103-6. PubMed ID: 16732964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes.
    Czechowska A; Poplawski T; Drzewoski J; Blasiak J
    Chem Biol Interact; 2005 Apr; 152(2-3):139-50. PubMed ID: 15840387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells.
    Kominsky DJ; Klawitter J; Brown JL; Boros LG; Melo JV; Eckhardt SG; Serkova NJ
    Clin Cancer Res; 2009 May; 15(10):3442-50. PubMed ID: 19401345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
    Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P
    Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
    Sun B; Jiang G; Zaydan MA; La Russa VF; Safah H; Ehrlich M
    Cancer Res; 2001 Sep; 61(18):6931-7. PubMed ID: 11559572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of bcr/abl mRNA expression by a rapid real-time reverse transcription-polymerase chain reaction assay in patients with chronic myeloid leukemia.
    Zanella I; Rossi G; Finazzi D; Capucci A; Albertini A; Cariani E
    Haematologica; 2001 Mar; 86(3):318-9. PubMed ID: 11255281
    [No Abstract]   [Full Text] [Related]  

  • 11. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
    Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
    Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi).
    Wilda M; Fuchs U; Wössmann W; Borkhardt A
    Oncogene; 2002 Aug; 21(37):5716-24. PubMed ID: 12173041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
    Radojkovic M; Ristic S; Pavlovic S; Colovic M
    Leuk Res; 2009 Jun; 33(6):e10-2. PubMed ID: 19091403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
    Huang HM; Liu JC
    J Cell Physiol; 2009 Mar; 218(3):568-74. PubMed ID: 19006173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcr-Abl-independent mechanism of resistance to imatinib in K562 cells: Induction of cyclooxygenase-2 (COX-2) by histone deacetylases (HDACs).
    Kalle AM; Sachchidanand S; Pallu R
    Leuk Res; 2010 Sep; 34(9):1132-8. PubMed ID: 20206383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL-positive) cells sensitive and resistant to imatinib.
    Mor-Tzuntz R; Uziel O; Shpilberg O; Lahav J; Raanani P; Bakhanashvili M; Rabizadeh E; Zimra Y; Lahav M; Granot G
    Exp Hematol; 2010 Jan; 38(1):27-37. PubMed ID: 19837126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
    Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
    Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
    Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE
    Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
    Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
    Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.